Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol
Timothy E Albertson,1–3 Richart Harper,1,2 Susan Murin,1,2 Christian Sandrock1 1Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, School of Medicine, University of California, Davis, Sacramento, CA, USA; 2Department of Medicine, Veterans Ad...
Main Authors: | Albertson TE, Harper R, Murin S, Sandrock C |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-02-01
|
Series: | Patient Preference and Adherence |
Online Access: | http://www.dovepress.com/patient-considerations-in-the-treatment-of-copd-focus-on-the-new-combi-peer-reviewed-article-PPA |
Similar Items
-
Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD
by: Albertson TE, et al.
Published: (2019-06-01) -
Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
by: Molino A, et al.
Published: (2018-06-01) -
New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol
by: Cazzola M, et al.
Published: (2013-10-01) -
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
by: Nicola C. Day, et al.
Published: (2020-06-01) -
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
by: François Maltais, et al.
Published: (2019-10-01)